MOLN Molecular Partners AG

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.  

A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company's website. A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.

About Molecular Partners AG  Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com 

Find us on Twitter - @MolecularPrtnrsFor further details, please contact: Seth Lewis, SVP Investor Relations & Strategy Concord, Massachusetts, U.S. seth.lewis@molecularpartners.com  Tel: +1 781 420 2361 

Laura Jeanbart, PhD, Head of Portfolio Management & Communications  Zurich-Schlieren, Switzerland laura.jeanbart@molecularpartners.com   Tel: +41 44 575 19 35